Literature DB >> 10654175

Subretinal fibrosis and choroidal neovascularization in Vogt-Koyanagi-Harada syndrome.

S Lertsumitkul1, S M Whitcup, R B Nussenblatt, C C Chan.   

Abstract

BACKGROUND: To describe clinical findings of subretinal fibrosis and choroidal neovascularization in patients with Vogt-Koyanagi-Harada (VKH) syndrome.
METHODS: We retrospectively reviewed 75 medical records of patients with VKH seen at the National Eye Institute, Bethesda, Maryland between 1978 and 1996. Recorded data included age, gender, race, duration of disease, extraocular manifestations, best-corrected visual acuity, slit-lamp biomicroscopy, retinal examination, retinal photographs and fluorescein angiograms. We sought features that correlated with the visual outcome.
RESULTS: Thirty of 75 (40%) patients developed subretinal fibrosis. Eleven patients (14.7%) had choroidal neovascularization. Presence of subretinal fibrosis was associated with a longer duration of the disease (42.6 vs 19.1 months, P = 0.07). Patients with subretinal fibrosis had worse visual acuity than those without subretinal fibrosis (26.2 vs 57.3 ETDRS letters read, P < 0.001) after adjusting for duration of disease (P = 0.021), degree of vitreous haze (P = 0.074), and use of immunosuppressive therapy (P = 0.008).
CONCLUSIONS: Presence of subretinal fibrosis in patients with VKH is associated with a poor visual prognosis. The diagnosis of choroidal neovascularization and subretinal fibrosis presents a challenge in the management of this disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10654175     DOI: 10.1007/s004170050342

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  12 in total

Review 1.  The role of sex in uveitis and ocular inflammation.

Authors:  Ian Y L Yeung; Nicholas A Popp; Chi-Chao Chan
Journal:  Int Ophthalmol Clin       Date:  2015

2.  Photodynamic therapy for subfoveal choroidal neovascularisation in Vogt-Koyanagi-Harada disease.

Authors:  S R Nowilaty; M Bouhaimed
Journal:  Br J Ophthalmol       Date:  2006-05-10       Impact factor: 4.638

3.  The spectrum of Vogt-Koyanagi-Harada disease in Turkey: VKH in Turkey.

Authors:  Ilknur Tugal-Tutkun; Yilmaz Ozyazgan; Yonca A Akova; Yuksel Sullu; Nurettin Akyol; Merih Soylu; Haluk Kazokoglu
Journal:  Int Ophthalmol       Date:  2006-09-07       Impact factor: 2.031

4.  High rate of clinical recurrence in patients with Vogt-Koyanagi-Harada disease treated with early high-dose corticosteroids.

Authors:  Viviane M Sakata; Felipe T da Silva; Carlos E Hirata; Maria Lucia C Marin; Helcio Rodrigues; Jorge Kalil; Rogerio A Costa; Joyce H Yamamoto
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-01-16       Impact factor: 3.117

5.  Intravitreal bevacizumab for choroidal neovascularization secondary to Vogt-Koyanagi-Harada syndrome.

Authors:  Lihteh Wu; Teodoro Evans; Mario Saravia; Ariel Schlaen; Cristobal Couto
Journal:  Jpn J Ophthalmol       Date:  2009-01-30       Impact factor: 2.447

6.  Vogt-Koyanagi-Harada syndrome associated with cutaneous malignant melanoma: an 11-year follow-up.

Authors:  Sabine Aisenbrey; Christoph Lüke; Helen D Ayertey; Salvatore Grisanti; Andreas Perniok; Richard Brunner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-11-14       Impact factor: 3.117

7.  The use of intravitreal ranibizumab for choroidal neovascularization associated with vogt-koyanagi-harada syndrome.

Authors:  A M Kolomeyer; M S Roy; D S Chu
Journal:  Case Rep Med       Date:  2011-08-03

Review 8.  Vogt-Koyanagi-Harada syndrome - current perspectives.

Authors:  Abeir Baltmr; Sue Lightman; Oren Tomkins-Netzer
Journal:  Clin Ophthalmol       Date:  2016-11-24

Review 9.  Gender differences in vogt-koyanagi-harada disease and sympathetic ophthalmia.

Authors:  Yujuan Wang; Chi-Chao Chan
Journal:  J Ophthalmol       Date:  2014-03-05       Impact factor: 1.909

Review 10.  Vogt-Koyanagi-Harada disease: review of a rare autoimmune disease targeting antigens of melanocytes.

Authors:  Marcelo Mendes Lavezzo; Viviane Mayumi Sakata; Celso Morita; Ever Ernesto Caso Rodriguez; Smairah Frutuoso Abdallah; Felipe T G da Silva; Carlos Eduardo Hirata; Joyce Hisae Yamamoto
Journal:  Orphanet J Rare Dis       Date:  2016-03-24       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.